Volker Heinemann

43.8k total citations · 10 hit papers
666 papers, 20.3k citations indexed

About

Volker Heinemann is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Volker Heinemann has authored 666 papers receiving a total of 20.3k indexed citations (citations by other indexed papers that have themselves been cited), including 544 papers in Oncology, 236 papers in Pulmonary and Respiratory Medicine and 165 papers in Cancer Research. Recurrent topics in Volker Heinemann's work include Colorectal Cancer Treatments and Studies (294 papers), Pancreatic and Hepatic Oncology Research (166 papers) and Cancer Genomics and Diagnostics (129 papers). Volker Heinemann is often cited by papers focused on Colorectal Cancer Treatments and Studies (294 papers), Pancreatic and Hepatic Oncology Research (166 papers) and Cancer Genomics and Diagnostics (129 papers). Volker Heinemann collaborates with scholars based in Germany, United States and Italy. Volker Heinemann's co-authors include Stefan Boeck, Sebastian Stintzing, William Plunkett, Dominik Paul Modest, Hans‐Joachim Stemmler, Gerald B. Grindey, Larry W. Hertel, Heinz‐Josef Lenz, Michael Haas and Eric Van Cutsem and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Volker Heinemann

622 papers receiving 20.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

1995 646 citations Volker Heinemann et al. profile →
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer

2015 578 citations Eric Van Cutsem, Heinz‐Josef Lenz et al. Journal of Clinical Oncology profile →
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

2017 554 citations Heinz‐Josef Lenz, Volker Heinemann et al. Annals of Oncology profile →
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

2006 535 citations Volker Heinemann, D. Quietzsch et al. Journal of Clinical Oncology profile →
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer

2016 508 citations Sebastian Stintzing, Fortunato Ciardiello et al. profile →
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

2015 504 citations Volker Heinemann, Werner Scheithauer et al. profile →
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

2016 434 citations Tim Maughan, Cornelis J.A. Punt et al. profile →
Advances in cancer immunotherapy 2019 – latest trends

2019 400 citations Volker Heinemann, Stefan Boeck et al. profile →
Addressing the challenges of pancreatic cancer: Future directions for improving outcomes

2014 386 citations Volker Heinemann et al. profile →
The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials

2016 377 citations Ingrid Ricard, Sebastian Stintzing et al. European Journal of Cancer profile →

Peers

Countries citing papers authored by Volker Heinemann

Since Specialization

Citations

This map shows the geographic impact of Volker Heinemann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Volker Heinemann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Volker Heinemann more than expected).

Fields of papers citing papers by Volker Heinemann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Volker Heinemann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Volker Heinemann. The network helps show where Volker Heinemann may publish in the future.

Co-authorship network of co-authors of Volker Heinemann

This figure shows the co-authorship network connecting the top 25 collaborators of Volker Heinemann. A scholar is included among the top collaborators of Volker Heinemann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Volker Heinemann. Volker Heinemann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identification of a gene expression signature associated with brain metastasis in colorectal cancer 2024 ·Clinical & Translational Oncology ·Marlies Michl, (unknown), (unknown), (unknown), Frederick Klauschen, Thomas Kirchner, Volker Heinemann, Michael von Bergwelt‐Baildon, Arndt Stahler, (unknown), Vindi Jurinović, Jutta Engel, Jörg Kumbrink, Jens Neumann	3
2	Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of RAS wild-type (WT) metastatic colorectal cancer (mCRC): Pooled analysis of the randomized trials FIRE-1, FIRE-3, XELAVIRI, and PanaMa. 2024 ·Journal of Clinical Oncology ·Arndt Stahler, Dominik Paul Modest, Sebastian Stintzing, Swantje Held, Ludwig Fischer von Weikersthal, Lothar Müller, Ullrich Graeven, Thomas Decker, Tobias Heintges, Christoph Kahl, Werner Scheithauer, Alexander Kiani, Florian Kaiser, Ingo Schwaner, (unknown), (unknown), (unknown), (unknown), David Horst, Volker Heinemann	0
3	Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212) 2024 ·Clinical Cancer Research ·Arndt Stahler, (unknown), Christine Sers, Soulafa Mamlouk, Lothar Müller, (unknown), (unknown), Ullrich Graeven, Ludwig Fischer von Weikersthal, (unknown), Stefan Kasper, (unknown), Annika Kurreck, Swantje Held, Volker Heinemann, David Horst, (unknown), Sebastian Stintzing, (unknown), Dominik Paul Modest	9
4	Bridging the gap: Leveraging telemedicine and IT infrastructure to connect outpatient oncology practices with specialized expert teams in the management of rare tumors 2024 ·Digital Health ·(unknown), (unknown), Karin Berger, (unknown), (unknown), Sven P. Wichert, (unknown), (unknown), Michael von Bergwelt‐Baildon, Volker Heinemann, Hana Algül, (unknown), (unknown), (unknown)	0
5	Implementing precision oncology for sarcoma patients: the CCCLMUmolecular tumor board experience 2023 ·Journal of Cancer Research and Clinical Oncology ·(unknown), (unknown), Philipp Lange, Dorit Di Gioia, M. Schmidt, Thomas Knösel, Frederick Klauschen, Michael von Bergwelt‐Baildon, Volker Heinemann, Philipp A. Greif, C. Benedikt Westphalen, Kathrin Heinrich, Lars H. Lindner	3
6	Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer 2023 ·ESMO Open ·Cornelis J.A. Punt, Volker Heinemann, Tim Maughan, Chiara Cremolini, Eric Van Cutsem, Ray McDermott, (unknown), Thierry André, Pia Österlund, Arco J. Teske, Per Pfeiffer	4
7	SO-6 Changes in the course of advanced pancreatic cancer treatment with systemic chemotherapy: A pooled analysis of five clinical trials from two decades of clinical research within the German AIO Study-Group 2023 ·Annals of Oncology ·(unknown), Volker Heinemann, Laura Fischer, Frank Gieseler, Thomas Hoehler, Julia Mayerle, D. Quietzsch, Anke Reinacher‐Schick, Michael Schenk, G. Seipelt, Jens T. Siveke, Michael Stahl, Ursula Vehling‐Kaiser, Dirk Waldschmidt, Klara Dorman, (unknown), C. Benedikt Westphalen, Michael Haas, Stefan Boeck	1
8	Clinical and quality of life outcomes with trifluridine/tipiracil: PRECONNECT and TALLISUR studies 2023 ·Lucjan Wyrwicz, Julien Taı̈eb, Timothy Price, (unknown), Meinolf Karthaus, Loïck Vidot, (unknown), Timo Reisländer, (unknown), Volker Heinemann	1
9	First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer – Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110) 2022 ·European Journal of Cancer ·Arndt Stahler, Dominik Paul Modest, Ludwig Fischer von Weikersthal, Florian Kaiser, Thomas Decker, Swantje Held, Ullrich Graeven, Ingo Schwaner, Claudio Denzlinger, Michael Schenk, Annika Kurreck, Kathrin Heinrich, Clemens Gießen-Jung, Jens Neumann, Thomas Kirchner, Andreas Jung, Sebastian Stintzing, Volker Heinemann	1
10	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC 2021 ·Molecular Cancer Therapeutics ·Hiroyuki Arai, Shu Cao, Francesca Battaglin, (unknown), Natsuko Kawanishi, Ryuma Tokunaga, Fotios Loupakis, Sebastian Stintzing, Shivani Soni, Wu Zhang, Christoph Mancao, Bodour Salhia, Shannon M. Mumenthaler, Chiara Cremolini, Volker Heinemann, Alfredo Falcone, Joshua Millstein, Heinz‐Josef Lenz	0
11	Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial) 2021 ·European Journal of Cancer ·Arndt Stahler, Volker Heinemann, (unknown), Kathrin Heinrich, Annika Kurreck, Clemens Gießen-Jung, Ludwig Fischer von Weikersthal, Florian Kaiser, Thomas Decker, Swantje Held, Ullrich Graeven, Ingo Schwaner, Claudio Denzlinger, Michael Schenk, Jens Neumann, Thomas Kirchner, Andreas Jung, Jörg Kumbrink, Sebastian Stintzing, Dominik Paul Modest	4
12	Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials 2020 ·Clinical Cancer Research ·Arndt Stahler, Sebastian Stintzing, Dominik Paul Modest, Ingrid Ricard, Clemens Gießen-Jung, (unknown), (unknown), Florian Kaiser, Ludwig Fischer von Weikersthal, Nicolas Moosmann, Andreas Schalhorn, Martina Stauch, Alexander Kiani, Swantje Held, Thomas Decker, Markus Moehler, Jens Neumann, Thomas Kirchner, Andreas Jung, Volker Heinemann	20
13	Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer 2018 ·Clinical Cancer Research ·Pierre Laurent‐Puig, (unknown), Volker Heinemann, (unknown), Daniel Neureiter, Andreas Jung, François Montestruc, Yann Gaston‐Mathé, Raphaële Thiébaut, Sebastian Stintzing	31
14	The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer 2018 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Jens Neumann, Volker Heinemann, Jutta Engel, Thomas Kirchner, Sebastian Stintzing	16
15	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab 2017 ·Clinical Cancer Research ·Martin D. Berger, Sebastian Stintzing, Volker Heinemann, Shu Cao, Dongyun Yang, Yu Sunakawa, Satoshi Matsusaka, Yan Ning, Satoshi Okazaki, Yuji Miyamoto, Mitsukuni Suenaga, Marta Schirripa, Diana L. Hanna, Shivani Soni, Alberto Puccini, Wu Zhang, Chiara Cremolini, Alfredo Falcone, Fotios Loupakis, Heinz‐Josef Lenz	21
16	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer 2015 ·Molecular Cancer Therapeutics ·Sebastian Stintzing, Wu Zhang, Volker Heinemann, Daniel Neureiter, Ralf Kemmerling, Thomas Kirchner, Andreas Jung, Matthias Folwaczny, Dongyun Yang, Yan Ning, Ana Sebio, Stefan Stremitzer, Yu Sunakawa, Satoshi Matsusaka, Shinichi Yamauchi, Fotios Loupakis, Chiara Cremolini, Alfredo Falcone, Heinz‐Josef Lenz	5
17	Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer breakdown → 2015 ·Journal of Clinical Oncology ·Eric Van Cutsem, Heinz‐Josef Lenz, Claus-Henning Köhne, Volker Heinemann, Sabine Tejpar, I. Melezínek, Frank Beier, Christopher Stroh, Philippe Rougier, J. Han van Krieken, Fortunato Ciardiello	578
18	Surrogate endpoints in second-line treatment for mCRC: A systematic literature-based analysis from 23 randomised trials 2014 ·Acta Oncologica ·Clemens Gießen, Ruediger P. Laubender, Donna P. Ankerst, Sebastian Stintzing, Dominik Paul Modest, Christoph Schulz, Ulrich Mansmann, Volker Heinemann	16
19	Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials 2012 ·Clinical Cancer Research ·Clemens Gießen, Ruediger P. Laubender, Donna P. Ankerst, Sebastian Stintzing, Dominik Paul Modest, Ulrich Mansmann, Volker Heinemann	55
20	UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer 2009 ·World Journal of Gastroenterology ·Christoph Schulz, Volker Heinemann, Andreas Schalhorn, (unknown), Thomas Zwingers, Stefan Boeck, Clemens Gießen, Hans‐Joachim Stemmler	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact